BB-101

Phase 2Biologic

BBlue Blood Biotech Corp.

BB-101 is one of 3 biologic programs targeting Diabetic Foot Ulcer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Foot UlcerRecruiting

Diabetic Foot UlcerPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Diabetic Foot Ulcer

#DrugCompanyPhaseTrials

L-Carnitine

IIperboreal Pharma Srl

Phase 2

1 2

BB-101

BBlue Blood Biotech Corp.

Phase 2

1 3

Propolis

IIndonesia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Diabetic Foot Ulcer

NCT06383013

Clinical

Trials by Indication[1]

Treatment1 trial

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

Completed·BBlue Blood Biotech Corp.·Phase 1·NCT03888053·14 enrolled

Diabetic Foot Ulcer1 trial

Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Recruiting·BBlue Blood Biotech Corp.·Phase 2·NCT06383013·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BB-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BB-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BB-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blue Blood Biotech Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBlue Blood Biotech Corp.

BB-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Treatment1 trial

Diabetic Foot Ulcer1 trial

References

Drug Info

Quick Facts

Related News